Niacin/Laropiprant Products to Be Suspended WorldwideNiacin/Laropiprant Products to Be Suspended Worldwide

The European's Medicines Agency is likely the first of many to propose the suspension of niacin/laropiprant products for dyslipidemia following the failure of the HPS-2 THRIVE trial; Merck confirms it will suspend availability of the medicine where it is available. News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news